vs

Side-by-side financial comparison of Exodus Movement, Inc. (EXOD) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Exodus Movement, Inc. is the larger business by last-quarter revenue ($29.4M vs $19.6M, roughly 1.5× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -181.0%, a 3.6% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -34.4%). STANDARD BIOTOOLS INC. produced more free cash flow last quarter ($-23.1M vs $-25.8M). Over the past eight quarters, Exodus Movement, Inc.'s revenue compounded faster (0.6% CAGR vs -12.2%).

Exodus is a cryptocurrency wallet available on desktop and mobile platforms. It was founded in 2015 by JP Richardson and Daniel Castagnoli. Exodus wallet supports digital assets including Bitcoin, Ethereum, and Solana. It is available on Windows, macOS, Linux, iOS, Android, and as a browser extension.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

EXOD vs LAB — Head-to-Head

Bigger by revenue
EXOD
EXOD
1.5× larger
EXOD
$29.4M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+22.9% gap
LAB
-11.5%
-34.4%
EXOD
Higher net margin
LAB
LAB
3.6% more per $
LAB
-177.4%
-181.0%
EXOD
More free cash flow
LAB
LAB
$2.7M more FCF
LAB
$-23.1M
$-25.8M
EXOD
Faster 2-yr revenue CAGR
EXOD
EXOD
Annualised
EXOD
0.6%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
EXOD
EXOD
LAB
LAB
Revenue
$29.4M
$19.6M
Net Profit
$-53.2M
$-34.7M
Gross Margin
48.5%
Operating Margin
-226.9%
-168.5%
Net Margin
-181.0%
-177.4%
Revenue YoY
-34.4%
-11.5%
Net Profit YoY
-179.5%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXOD
EXOD
LAB
LAB
Q4 25
$29.4M
Q3 25
$30.3M
$19.6M
Q2 25
$25.8M
$21.8M
Q1 25
$36.0M
$40.8M
Q4 24
$44.8M
Q3 24
$20.1M
$22.1M
Q2 24
$22.3M
$22.5M
Q1 24
$29.1M
$45.5M
Net Profit
EXOD
EXOD
LAB
LAB
Q4 25
$-53.2M
Q3 25
$17.0M
$-34.7M
Q2 25
$37.7M
$-33.5M
Q1 25
$-12.9M
$-26.0M
Q4 24
$66.9M
Q3 24
$843.0K
$-26.9M
Q2 24
$-9.6M
$-45.7M
Q1 24
$54.8M
$-32.2M
Gross Margin
EXOD
EXOD
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
43.7%
54.9%
Q2 24
51.7%
46.1%
Q1 24
63.2%
53.1%
Operating Margin
EXOD
EXOD
LAB
LAB
Q4 25
-226.9%
Q3 25
66.9%
-168.5%
Q2 25
-118.1%
Q1 25
-60.4%
-80.8%
Q4 24
Q3 24
-0.3%
-120.9%
Q2 24
-66.1%
-134.5%
Q1 24
-132.2%
Net Margin
EXOD
EXOD
LAB
LAB
Q4 25
-181.0%
Q3 25
56.2%
-177.4%
Q2 25
145.8%
-153.7%
Q1 25
-35.8%
-63.8%
Q4 24
149.4%
Q3 24
4.2%
-122.0%
Q2 24
-43.1%
-203.3%
Q1 24
188.5%
-70.6%
EPS (diluted)
EXOD
EXOD
LAB
LAB
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXOD
EXOD
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$4.9M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$247.4M
$399.7M
Total Assets
$266.8M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXOD
EXOD
LAB
LAB
Q4 25
$4.9M
Q3 25
$50.5M
$129.4M
Q2 25
$52.9M
$158.6M
Q1 25
$59.8M
$150.9M
Q4 24
$37.9M
Q3 24
$26.5M
$210.6M
Q2 24
$27.8M
$269.8M
Q1 24
$21.0M
$287.1M
Total Debt
EXOD
EXOD
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
EXOD
EXOD
LAB
LAB
Q4 25
$247.4M
Q3 25
$296.7M
$399.7M
Q2 25
$277.1M
$424.5M
Q1 25
$241.5M
$454.6M
Q4 24
$257.5M
Q3 24
$191.2M
$489.3M
Q2 24
$190.8M
$510.3M
Q1 24
$199.1M
$577.3M
Total Assets
EXOD
EXOD
LAB
LAB
Q4 25
$266.8M
Q3 25
$338.5M
$539.6M
Q2 25
$313.7M
$557.0M
Q1 25
$263.2M
$579.6M
Q4 24
$288.0M
Q3 24
$211.6M
$681.5M
Q2 24
$211.6M
$708.7M
Q1 24
$225.4M
$777.7M
Debt / Equity
EXOD
EXOD
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXOD
EXOD
LAB
LAB
Operating Cash FlowLast quarter
$-25.6M
$-22.2M
Free Cash FlowOCF − Capex
$-25.8M
$-23.1M
FCF MarginFCF / Revenue
-87.9%
-118.1%
Capex IntensityCapex / Revenue
0.9%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.3M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXOD
EXOD
LAB
LAB
Q4 25
$-25.6M
Q3 25
$-4.8M
$-22.2M
Q2 25
$-5.3M
$-20.7M
Q1 25
$-6.2M
$-30.3M
Q4 24
$-12.0M
Q3 24
$-4.9M
$-27.9M
Q2 24
$-2.4M
$-39.0M
Q1 24
$450.0K
$-62.5M
Free Cash Flow
EXOD
EXOD
LAB
LAB
Q4 25
$-25.8M
Q3 25
$-4.8M
$-23.1M
Q2 25
$-5.4M
$-22.6M
Q1 25
$-6.2M
$-35.3M
Q4 24
$-12.3M
Q3 24
$-4.9M
$-30.1M
Q2 24
$-2.4M
$-41.0M
Q1 24
$300.0K
$-63.3M
FCF Margin
EXOD
EXOD
LAB
LAB
Q4 25
-87.9%
Q3 25
-16.0%
-118.1%
Q2 25
-20.7%
-103.6%
Q1 25
-17.3%
-86.6%
Q4 24
-27.5%
Q3 24
-24.5%
-136.4%
Q2 24
-10.8%
-182.2%
Q1 24
1.0%
-138.9%
Capex Intensity
EXOD
EXOD
LAB
LAB
Q4 25
0.9%
Q3 25
0.1%
4.5%
Q2 25
0.4%
8.7%
Q1 25
0.1%
12.4%
Q4 24
0.6%
Q3 24
0.2%
10.2%
Q2 24
0.2%
8.6%
Q1 24
0.5%
1.7%
Cash Conversion
EXOD
EXOD
LAB
LAB
Q4 25
Q3 25
-0.28×
Q2 25
-0.14×
Q1 25
Q4 24
-0.18×
Q3 24
-5.80×
Q2 24
Q1 24
0.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXOD
EXOD

Exchange Aggregation$26.6M90%
Other$2.8M10%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons